
-
2013
Company Description
Curasight is focused on developing novel and innovative PET imaging ligands for prostate cancer
Curasight is focused on developing novel and innovative PET imaging ligands for prostate cancer. PET imaging can provide basis for an informed choice of whether the patient should receive a prostate removal or not. Given the severe side effects of receiving a prostate removal, a secure method for identifying whether there is a need, is massive.
-
Manufacturer:
Science and Engineering -
Formed:
2013 -
Founders:
Andreas Kjaer -
Company Website:
-
Company E-mail:
-
Company Address:
Ole Maaløes Vej 3CopenhagenDenmark -
CEO:
- Andreas Kjaer
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits